Sanj Patel
Chief Executive Officer bei KINIKSA PHARMACEUTICALS, LTD.
Vermögen: 34 Mio $ am 31.03.2024
Profil
Sanj K.
Patel is the founder of the Sarcoma Foundation of America (founded in 2015) and Kiniksa Pharmaceuticals Ltd.
(founded in 2015).
He is currently the Chief Executive Officer & Director at Kiniksa Pharmaceuticals Corp.
In the past, he held positions such as President, Chief Executive Officer & Director at Synageva BioPharma Corp.
(2008-2015), Independent Director at BioCryst Pharmaceuticals, Inc. (2015-2018), Independent Director at Intercept Pharmaceuticals, Inc. (2014-2015), Independent Director at Syros Pharmaceuticals, Inc. (2016-2018), and Head-Global Clinical Research Operations Council at Genzyme Corp.
(1999-2008).
Mr. Patel has an undergraduate degree from London South Bank University and a graduate degree from Ealing Hammersmith & West London College.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
KINIKSA PHARMACEUTICALS LTD.
37,18% | 31.03.2023 | 1 526 160 ( 37,18% ) | 30 Mio $ | 31.03.2024 |
08.04.2024 | 172 807 ( 0,43% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Sanj Patel
Unternehmen | Position | Beginn |
---|---|---|
KINIKSA PHARMACEUTICALS, LTD. | Chief Executive Officer | 01.07.2015 |
Sarcoma Foundation of America | Founder | 01.01.2015 |
Kiniksa Pharmaceuticals Corp.
Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The private company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Chief Executive Officer | - |
Ehemalige bekannte Positionen von Sanj Patel
Unternehmen | Position | Ende |
---|---|---|
BIOCRYST PHARMACEUTICALS, INC. | Director/Board Member | 20.06.2018 |
SYROS PHARMACEUTICALS, INC. | Director/Board Member | 14.06.2018 |
INTERCEPT PHARMACEUTICALS, INC. | Director/Board Member | 24.11.2015 |
SYNAGEVA BIOPHARMA CORP | Chief Executive Officer | 22.06.2015 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2008 |
Ausbildung von Sanj Patel
London South Bank University | Undergraduate Degree |
Ealing Hammersmith & West London College | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
SYROS PHARMACEUTICALS, INC. | Health Technology |
KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
Private Unternehmen | 4 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Synageva BioPharma Corp.
Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Sarcoma Foundation of America | Miscellaneous |
Kiniksa Pharmaceuticals Corp.
Kiniksa Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Part of Kiniksa Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company that develops and commercializes therapeutic medicines for patients suffering from debilitating diseases. The private company is based in Lexington, MA. The CEO of the company is Sanj K. Patel. | Health Technology |